NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future
In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro
‘Be Careful We’re Not Fighting Old Battles’ On Study Section Issue
‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’
“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s
Centers Program Needs ‘Innovative Additions’ Such as SPORE Grants
Broder Not Satisfied With Mortality STATS On Three Major Cancers
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
